+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07098988

Evaluating Visugromab With Pembrolizumab, Pemetrexed, and Carboplatin in First-Line Treatment of Metastatic Non-Squamous NSCLC A Randomized, Placebo-Controlled Phase 2b Trial

Led by CatalYm GmbH · Updated on 2026-10-19

107

Participants Needed

51

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating Visugromab, an anti GDF-15 antibody, combined with immunochemotherapy in treating adults with newly diagnosed metastatic non-squamous non-small cell lung cancer NSCLC. This Phase 2b randomized, double-blind, placebo-controlled study aims to explore the safety and effectiveness of Visugromab plus standard immunochemotherapy compared to placebo with immunochemotherapy. The trial includes a safety-run-in phase followed by randomized treatment arms to gather preliminary efficacy and safety data.

CONDITIONS

Brief Title

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Research Team

F

Felix Lichtenegger, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here